Maverick Capital Ltd. Increases Stock Position in Humana Inc. (NYSE:HUM)

Maverick Capital Ltd. grew its holdings in shares of Humana Inc. (NYSE:HUM) by 41.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 191,570 shares of the insurance provider’s stock after buying an additional 55,733 shares during the period. Humana makes up 1.4% of Maverick Capital Ltd.’s investment portfolio, making the stock its 26th largest position. Maverick Capital Ltd.’s holdings in Humana were worth $71,580,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HUM. MBB Public Markets I LLC lifted its position in Humana by 8.5% during the 2nd quarter. MBB Public Markets I LLC now owns 119,760 shares of the insurance provider’s stock valued at $44,748,000 after acquiring an additional 9,430 shares during the period. Daymark Wealth Partners LLC increased its stake in shares of Humana by 41.6% during the second quarter. Daymark Wealth Partners LLC now owns 1,466 shares of the insurance provider’s stock valued at $548,000 after purchasing an additional 431 shares in the last quarter. Earnest Partners LLC lifted its holdings in shares of Humana by 5.8% during the second quarter. Earnest Partners LLC now owns 50,928 shares of the insurance provider’s stock valued at $19,029,000 after purchasing an additional 2,799 shares during the last quarter. APG Asset Management US Inc. lifted its holdings in shares of Humana by 3.0% during the second quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after purchasing an additional 1,955 shares during the last quarter. Finally, AXA S.A. boosted its position in shares of Humana by 285.1% in the 2nd quarter. AXA S.A. now owns 50,809 shares of the insurance provider’s stock worth $18,985,000 after purchasing an additional 37,614 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of analyst reports. Piper Sandler started coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Robert W. Baird initiated coverage on shares of Humana in a research note on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price target on the stock. TD Cowen raised their price objective on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. Thirteen investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $398.70.

Humana Price Performance

NYSE HUM opened at $313.04 on Friday. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The stock has a 50-day moving average of $352.81 and a 200 day moving average of $344.87. The company has a market capitalization of $37.72 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $8.94 EPS. On average, sell-side analysts forecast that Humana Inc. will post 16.01 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.13%. Humana’s dividend payout ratio is currently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.